Folks stroll previous an indication for Novo Nordisk’s annual basic assembly on the entrance to the venue in Copenhagen, Denmark, March 26, 2026.
Tom Little | Reuters
Novo Nordisk is partnering with OpenAI to “deliver new and higher therapy choices to sufferers quicker,” the Danish drugmaker stated Tuesday.
The partnership will allow Novo to higher use AI to research advanced datasets, determine promising new medication, and cut back the time it takes for a drugs to maneuver from the analysis stage to affected person use, the corporate stated in an announcement.
“There are thousands and thousands of individuals residing with weight problems and diabetes who want therapy choices, and we all know there are therapies nonetheless ready to be found that might change their lives,” stated Novo CEO Mike Doustdar. “Integrating AI in our on a regular basis work offers us the flexibility to analyse datasets at a scale that was beforehand not possible, determine patterns we couldn’t see, and check hypotheses quicker than ever.”
“AI is reshaping industries and in life sciences, it could assist folks reside higher, longer lives,” stated OpenAI CEO Sam Altman.
The inventory jumped 2.8% shortly after the opening bell.
It comes as drugmakers are more and more turning to AI to enhance operations and prolonged processes. Whereas AI might uncover new remedies, specialists say that the business remains to be removed from leveraging the expertise’s full potential and extra instant advantages might come from utilizing it in different areas of drug growth. AI can, for instance, assist firms within the time-consuming job of figuring out sufferers and websites for scientific trials.
“We have not heard the final of it but… by way of how scientific trials get designed and run, numerous it’s nonetheless very conventional, with sure factors the place AI is being leveraged,” Arthur D. Little associate Ben van der Schaaf, advised CNBC final month. “AI isn’t an end-to-end element but.”
Novo’s newest transfer builds on its present AI initiatives, which additionally embrace a collaboration with Nvidia to make use of the Gefion sovereign AI supercomputer to “speed up drug discovery efforts via revolutionary AI use circumstances.” The businesses stated final yr that they goal to create personalized AI fashions and brokers that Novo can use for early analysis and scientific growth.
Novo Nordisk is locked in a race with U.S. rival Eli Lilly for dominance within the profitable weight reduction market, through which it has misplaced its first-mover benefit. Novo is now making an attempt to claw again market share via its Wegovy tablet, launched in January, and next-generation medication.
